Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361211778> ?p ?o ?g. }
- W4361211778 endingPage "1042" @default.
- W4361211778 startingPage "1042" @default.
- W4361211778 abstract "Patients with antibody deficiency disorders, such as primary immunodeficiency (PID) or secondary immunodeficiency (SID) to B-cell lymphoproliferative disorder (B-CLPD), are two groups vulnerable to developing the severe or chronic form of coronavirus disease caused by SARS-CoV-2 (COVID-19). The data on adaptive immune responses against SARS-CoV-2 are well described in healthy donors, but still limited in patients with antibody deficiency of a different cause. Herein, we analyzed spike-specific IFN-γ and anti-spike IgG antibody responses at 3 to 6 months after exposure to SARS-CoV-2 derived from vaccination and/or infection in two cohorts of immunodeficient patients (PID vs. SID) compared to healthy controls (HCs). Pre-vaccine anti-SARS-CoV-2 cellular responses before vaccine administration were measured in 10 PID patients. Baseline cellular responses were detectable in 4 out of 10 PID patients who had COVID-19 prior to vaccination, perceiving an increase in cellular responses after two-dose vaccination (p < 0.001). Adequate specific cellular responses were observed in 18 out of 20 (90%) PID patients, in 14 out of 20 (70%) SID patients and in 74 out of 81 (96%) HCs after vaccination (and natural infection in some cases). Specific IFN-γ response was significantly higher in HC with respect to PID (1908.5 mUI/mL vs. 1694.1 mUI/mL; p = 0.005). Whereas all SID and HC patients mounted a specific humoral immune response, only 80% of PID patients showed positive anti-SARS-CoV-2 IgG. The titer of anti-SARS-CoV-2 IgG was significantly lower in SID compared with HC patients (p = 0.040), without significant differences between PID and HC patients (p = 0.123) and between PID and SID patients (p =0.683). High proportions of PID and SID patients showed adequate specific cellular responses to receptor binding domain (RBD) neoantigen, with a divergence between the two arms of the adaptive immune response in PID and SID patients. We also focused on the correlation of protection of positive SARS-CoV-2 cellular response to omicron exposure: 27 out of 81 (33.3%) HCs referred COVID-19 detected by PCR or antigen test, 24 with a mild course, 1 with moderate symptoms and the remaining 2 with bilateral pneumonia that were treated in an outpatient basis. Our results might support the relevance of these immunological studies to determine the correlation of protection with severe disease and for deciding the need for additional boosters on a personalized basis. Follow-up studies are required to evaluate the duration and variability in the immune response to COVID-19 vaccination or infection." @default.
- W4361211778 created "2023-03-31" @default.
- W4361211778 creator A5005269604 @default.
- W4361211778 creator A5008306999 @default.
- W4361211778 creator A5009864544 @default.
- W4361211778 creator A5016910009 @default.
- W4361211778 creator A5024657874 @default.
- W4361211778 creator A5032282735 @default.
- W4361211778 creator A5038457206 @default.
- W4361211778 creator A5039053084 @default.
- W4361211778 creator A5040372527 @default.
- W4361211778 creator A5040663702 @default.
- W4361211778 creator A5041412658 @default.
- W4361211778 creator A5049451072 @default.
- W4361211778 creator A5054639598 @default.
- W4361211778 creator A5059383103 @default.
- W4361211778 creator A5068795574 @default.
- W4361211778 creator A5069385617 @default.
- W4361211778 creator A5074810713 @default.
- W4361211778 creator A5076718355 @default.
- W4361211778 creator A5077220786 @default.
- W4361211778 creator A5084425257 @default.
- W4361211778 creator A5084702805 @default.
- W4361211778 creator A5089501338 @default.
- W4361211778 creator A5091522133 @default.
- W4361211778 date "2023-03-28" @default.
- W4361211778 modified "2023-10-18" @default.
- W4361211778 title "Specific Cellular and Humoral Immune Responses to the Neoantigen RBD of SARS-CoV-2 in Patients with Primary and Secondary Immunodeficiency and Healthy Donors" @default.
- W4361211778 cites W1903464412 @default.
- W4361211778 cites W2010386920 @default.
- W4361211778 cites W2063504654 @default.
- W4361211778 cites W2330913518 @default.
- W4361211778 cites W2497324662 @default.
- W4361211778 cites W2762077922 @default.
- W4361211778 cites W2805170482 @default.
- W4361211778 cites W2914208637 @default.
- W4361211778 cites W2968785079 @default.
- W4361211778 cites W3006355661 @default.
- W4361211778 cites W3019330774 @default.
- W4361211778 cites W3021544284 @default.
- W4361211778 cites W3033813936 @default.
- W4361211778 cites W3045721325 @default.
- W4361211778 cites W3092705824 @default.
- W4361211778 cites W3097738396 @default.
- W4361211778 cites W3118654820 @default.
- W4361211778 cites W3126498743 @default.
- W4361211778 cites W3161855925 @default.
- W4361211778 cites W3164747805 @default.
- W4361211778 cites W3172917217 @default.
- W4361211778 cites W3173641617 @default.
- W4361211778 cites W3194536759 @default.
- W4361211778 cites W3197315711 @default.
- W4361211778 cites W3206020366 @default.
- W4361211778 cites W3208699303 @default.
- W4361211778 cites W3211989315 @default.
- W4361211778 cites W3217201218 @default.
- W4361211778 cites W4206832934 @default.
- W4361211778 cites W4212869992 @default.
- W4361211778 cites W4225574157 @default.
- W4361211778 cites W4226227123 @default.
- W4361211778 cites W4281557772 @default.
- W4361211778 doi "https://doi.org/10.3390/biomedicines11041042" @default.
- W4361211778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37189660" @default.
- W4361211778 hasPublicationYear "2023" @default.
- W4361211778 type Work @default.
- W4361211778 citedByCount "0" @default.
- W4361211778 crossrefType "journal-article" @default.
- W4361211778 hasAuthorship W4361211778A5005269604 @default.
- W4361211778 hasAuthorship W4361211778A5008306999 @default.
- W4361211778 hasAuthorship W4361211778A5009864544 @default.
- W4361211778 hasAuthorship W4361211778A5016910009 @default.
- W4361211778 hasAuthorship W4361211778A5024657874 @default.
- W4361211778 hasAuthorship W4361211778A5032282735 @default.
- W4361211778 hasAuthorship W4361211778A5038457206 @default.
- W4361211778 hasAuthorship W4361211778A5039053084 @default.
- W4361211778 hasAuthorship W4361211778A5040372527 @default.
- W4361211778 hasAuthorship W4361211778A5040663702 @default.
- W4361211778 hasAuthorship W4361211778A5041412658 @default.
- W4361211778 hasAuthorship W4361211778A5049451072 @default.
- W4361211778 hasAuthorship W4361211778A5054639598 @default.
- W4361211778 hasAuthorship W4361211778A5059383103 @default.
- W4361211778 hasAuthorship W4361211778A5068795574 @default.
- W4361211778 hasAuthorship W4361211778A5069385617 @default.
- W4361211778 hasAuthorship W4361211778A5074810713 @default.
- W4361211778 hasAuthorship W4361211778A5076718355 @default.
- W4361211778 hasAuthorship W4361211778A5077220786 @default.
- W4361211778 hasAuthorship W4361211778A5084425257 @default.
- W4361211778 hasAuthorship W4361211778A5084702805 @default.
- W4361211778 hasAuthorship W4361211778A5089501338 @default.
- W4361211778 hasAuthorship W4361211778A5091522133 @default.
- W4361211778 hasBestOaLocation W43612117781 @default.
- W4361211778 hasConcept C137061746 @default.
- W4361211778 hasConcept C159654299 @default.
- W4361211778 hasConcept C202751555 @default.
- W4361211778 hasConcept C203014093 @default.
- W4361211778 hasConcept C22070199 @default.
- W4361211778 hasConcept C22889606 @default.
- W4361211778 hasConcept C2776969849 @default.